Spots Global Cancer Trial Database for theranostic
Every month we try and update this database with for theranostic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6 | NCT06228482 | Metastatic Nons... | [68Ga]Ga DOTA-5... | 18 Years - | University of California, Davis | |
| ProsTIC Registry of Men Treated With PSMA Theranostics | NCT04769817 | Prostate Cancer Metastatic Cast... | 177Lu-PSMA | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | NCT06247995 | Breast Cancer | [68Ga]Ga-NeoB [177Lu]Lu-NeoB Capecitabine | 18 Years - | Novartis | |
| 68Ga-DOTA-FAPI and 177Lu-DOTA-FAPI Theranostic Pair in Patients With Various Types of Cancer (Locally Advanced or Metastatic Cancer) | NCT04849247 | 177Lu-DOTA-FAPI 68Ga-DOTA-FAPI Theranostic | 68Ga-DOTA-FAPI,... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | NCT06247995 | Breast Cancer | [68Ga]Ga-NeoB [177Lu]Lu-NeoB Capecitabine | 18 Years - | Novartis | |
| Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors | NCT03044977 | Neuroendocrine ... Neuroendocrine ... | 90Y-DOTA-3-Tyr-... 131I-MIBG | 18 Years - 80 Years | University of Iowa | |
| A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | NCT05363605 | Advanced Solid ... Head and Neck S... Bladder Carcino... Susceptible FGF... FGFR3 FGFR3 Overexpre... FGFR3 Receptor FGFR3 Protein O... Ovarian Cancer Colorectal Canc... Breast Cancer Liver Cancer Lung Cancer Gastric Cancer | [225Ac]-FPI-196... [111In]-FPI-196... vofatamab | 18 Years - | Fusion Pharmaceuticals Inc. | |
| ProsTIC Registry of Men Treated With PSMA Theranostics | NCT04769817 | Prostate Cancer Metastatic Cast... | 177Lu-PSMA | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy | NCT04904120 | Melanoma (Skin) Melanoma Stage ... Melanoma, Uveal Melanoma, Mucos... | [203Pb]VMT01 [68Ga]VMT02 | 18 Years - 89 Years | Perspective Therapeutics | |
| A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) | NCT04939610 | Solid Tumor | 68Ga-FAP-2286 177Lu-FAP-2286 | 18 Years - | Novartis | |
| First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer | NCT04665947 | Metastatic Panc... Locally Advance... | [68Ga]Ga DOTA-5... | 18 Years - | University of California, Davis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
